Search Results - technology+classifications+%3e+therapeutic+modalities+%3e+therapeutic+delivery+platforms

96 Results

Sort By:

Dextran Hydrogel Scaffolds Enhance Angiogenic Responses and Promote Complete Skin Regeneration During Burn Wound Healing

Unmet Need:Third-degree burns involve damage to both the epidermal and dermal layers and may also entail damage to underlying muscles, bones, and tendons. Such burns heal with thick scars, which result in contractures that distort the surrounding tissue. Deep third-degree burns usually require skin grafting to achieve wound closure, but the cosmetic...

Published: 5/9/2024 | Inventor(s): Guoming Sun, Xianjie Zhang, John Harmon, Sharon Gerecht

Keywords(s): Disease Indication, Drug Delivery Vehicle, Hydrogel, Therapeutic Matter, Therapeutics, Wound Healing

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Wound Healing, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities

Compositions of Kinetic Nanoparticles containing Nucleic Acids, Polycations, and Lipids with Defined Sizes, and Methods of Producing the Same

Value Proposition:· Scalable, efficient, and tunable nanoparticle creation technique that can deliver a variety of payloads· Polymer-lipid nanoparticles are biodegradable and are being tested for immunogenicity· Can be used for in vivo gene therapy delivery as well as in vitro cell transfection and research applications Technology...

Published: 5/10/2024 | Inventor(s): Hai-Quan Mao, Stephany Tzeng, Jordan Green, Yizong Hu, Sashank Reddy, Leonardo Cheng

Keywords(s):

Novel Bioreducible Polymer for Nucleic Acid Delivery to Eyes and Beyond

Unmet NeedInherited retinal diseases (IRDs) are a group of disorders with genetic and clinical heterogeneity and are the leading cause of vision loss. [1, 20] ] Collectively, IRDs have an estimated incidence of 1:2000. [1] Gene therapies targeting IRD, including FDA approved Luxturna, are injected directly into the retina to correct the underlying genetic...

Published: 5/10/2024 | Inventor(s): Jung Soo Suk, Gijung Kwak, Kai Zhang

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Ophthalmology

Method for using alternative splicing to control specificity of gene therapy

Unmet NeedViral-based gene therapy holds tremendous promise for the treatment of human diseases. Using genetically engineered carriers called vectors to deliver genes into cells, gene therapy can help replace a mutated gene with a healthy copy or even introduce a new gene into the body to fight a disease. However, an important concern when designing...

Published: 5/9/2024 | Inventor(s): Jonathan Ling, Seth Blackshaw

Keywords(s): Drug Delivery Mechanism, Gene Therapy, Single, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Research Tools > Vectors & Plasmids

Nanocrystal-based Suspension Formulation of Nintedanib for Inhaled Treatment of Silicosis and other Fibrotic Lung Diseases

Value Proposition· Intranasal inhaled formulation of nintedanib (NTB) allows for more targeted dosing.· Minimizes risk of systemic adverse events in the lung.· Enhances drug retention in the lung for local treatment via inhalation.· Formulation allows for long-term storage and remote shipping.· Surface-stabilized with...

Published: 5/10/2024 | Inventor(s): Jung Soo Suk, Luisa Andrade da Silva, Patricia Rocco, Marcelo Morales

Keywords(s):

Category(s): Clinical and Disease Specializations > Fibrosis, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Repurposed Drugs

Polymeric Nanoparticle Genetic Vaccines

Value PropositionVersatile immunotherapy platform with the ability to specifically target antigen presenting cells (APCs) ) following systemic delivery and without requiring targeting ligands to improve treatment efficacy. Flexibility to modulate the immune system through activation or inducing tolerance.Useful as a preventative strategy or therapeutic...

Published: 5/10/2024 | Inventor(s): Jordan Green, Elana Ben-Akiva, Johan Karlsson, Stephany Tzeng, Kelly Rhodes, Sarah Neshat

Keywords(s):

Category(s): Clinical and Disease Specializations > Autoimmunity, Clinical and Disease Specializations > Immunology, Technology Classifications > Medical Devices > Therapeutic Devices, Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Vaccines

Peptide for the Prevention and Treatment of Coronavirus Infection

Value Proposition· Peptide-based supramolecular filament that attenuates SARS-CoV virus infectivity in vivo· Leverages ACE2 enzyme-substrate docking activity· Enables therapeutic protein delivery in repairable aerosolsUnmet Need· Respiratory illnesses, including tuberculosis, influenza, and COVID-19, pose a significant worldwide...

Published: 5/10/2024 | Inventor(s): Honggang Cui, Hongpeng Jia, Caleb Anderson

Keywords(s):

Category(s): Clinical and Disease Specializations > Respiratory Diseases, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities > Vaccines, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms

Culture-derived EVs for targeted delivery and treatment of B cell diseases

Value Proposition· Purified EVs with preferential targeting for B cells in both ex-vivo and in-vivo applications.· EVs have half-life between 30-40 minutes, longer than many comparable extracellular vesicles.· EVs purified from cell culture medium to increase throughput, speed, and development of B-cell targeted therapies. Technology...

Published: 5/10/2024 | Inventor(s): Kenneth Witwer, Tom Driedonks, Erin Shirk, Linglei Jiang

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms

Improving the sensitivity of CRISPR off-target detection through modulation of DNA repair

Value Proposition:· Utilizes components of existing workflow to better detect off-target gene editing· Capable for use in in vivo or in vitro settings· Maximizes impact of CRISPR-Cas9 in therapeutic developmentTechnology Description· Researchers at Johns Hopkins have developed a method to detect off-target editing with high...

Published: 5/10/2024 | Inventor(s): Roger Zou, Yang Liu, Taekjip Ha, Oscar Reyes Gaido

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Cell Therapies, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms

Oral Delivery of Biologics Using Ingestible Microinjectors

Technology Description· Researchers at Johns Hopkins have developed methods for delivering oral formulations of traditionally parenteral medications (e.g., insulin, infliximab).· After oral delivery, autonomous microscale injectors are triggered by physiological cues in the intestine to steadily release macromolecular pharmaceuticals through...

Published: 5/10/2024 | Inventor(s): David Gracias, Florin Selaru, Arijit Ghosh

Keywords(s):

Category(s): Clinical and Disease Specializations > Diabetes, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms

1 2 3 4 5 6 7 8 9 10